肾去神经支配市场－全球产业规模、份额、趋势、机会和预测，按技术、产品、治疗领域、最终用户、地区和竞争细分，2020 年至 2030 年

2024 年全球肾臟去神经支配市场价值为 5.1234 亿美元，预计到 2030 年将达到 8.7385 亿美元，预测期内的复合年增长率为 9.45%。全球肾臟去神经支配市场正在经历显着增长，这得益于高血压盛行率的上升以及药物治疗在治疗难治性病例方面的局限性。肾臟去神经支配透过针对肾动脉中过度活跃的交感神经提供了一种新方法，为对传统药物反应不佳的患者提供了替代治疗方法。人口老化加剧、人们对非药物治疗方案认识的提高以及导管技术的进步（提高了手术的安全性和有效性）都推动了这一需求。射频、超音波和化学消融方法的创新扩大了治疗范围，使该手术对医疗保健提供者和寻求长期解决血压失控问题的患者更具吸引力。市场扩张也受到越来越多的临床试验的影响，这些临床试验证实了肾去神经术在降低不同患者群体（包括未服用抗高血压药物的患者）血压方面的益处。医院、专科诊所和门诊手术中心越来越多地将这种疗法纳入其心血管护理方案。随着监管部门的批准日益广泛，以及医疗保健系统致力于减轻慢性高血压的经济负担，肾去神经术预计将在全球范围内获得更大的发展。随着研发投入的增加和医生认知度的提高，市场有望稳定成长。

关键市场驱动因素

高血压盛行率上升

主要市场挑战

缺乏长期临床资料

主要市场趋势

技术进步有利于超音波和微输注

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球肾臟去神经支配市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依技术分类（超音波消融、射频消融、药物消融、微灌注）
  • 依产品（导管、单电极导管、多电极导管、射频产生器、其他）
  • 依治疗领域（高血压、心臟衰竭、糖尿病、肾衰竭、其他）
  • 按最终使用者（医院和诊所、门诊护理中心、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图
  • 依技术
  • 按产品
  • 按治疗领域
  • 按最终用户
  • 按地区

第六章：北美肾臟去神经市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第七章：欧洲肾臟去神经市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太肾臟去神经市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美洲肾臟去神经市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲肾臟去神经市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 併购
• 产品发布

第 13 章：竞争格局

• Medtronic Plc.
• Boston Scientific Corporation
• Abbott Laboratories, Inc.
• Terumo Corporation
• Johnson & Johnson
• Cordis Corporation
• ReCor Medical, Inc. (Otsuka Holdings)
• Cardiosonic Ltd
• Mercator MedSystems, Inc
• Renal Dynamics Limited

第 14 章：策略建议

第15章调查会社について・免责事项

Global Renal Denervation Market was valued at USD 512.34 Million in 2024 and is expected to reach USD 873.85 Million by 2030 with a CAGR of 9.45% during the forecast period. The global renal denervation market is witnessing significant growth driven by the increasing prevalence of hypertension and the limitations of pharmacological therapies in managing resistant cases. Renal denervation offers a novel approach by targeting the overactive sympathetic nerves in the renal arteries, providing an alternative treatment for patients who fail to respond adequately to conventional medications. The demand is supported by a growing aging population, rising awareness of non-pharmacologic treatment options, and advancements in catheter-based technologies that enhance procedural safety and efficacy. Innovation in radiofrequency, ultrasound, and chemical-based ablation methods has expanded the scope of treatment, making the procedure more appealing to healthcare providers and patients seeking long-term solutions to uncontrolled blood pressure. Market expansion is also influenced by the growing number of clinical trials validating the benefits of renal denervation in reducing blood pressure across various patient groups, including those not on antihypertensive drugs. Hospitals, specialty clinics, and ambulatory surgical centers are increasingly incorporating this therapy into their cardiovascular care protocols. As regulatory approvals become more widespread and healthcare systems seek to reduce the economic burden of chronic hypertension, renal denervation is expected to gain more traction globally. The market is positioned for steady growth with increasing investments in R&D and expanding awareness among physicians.

Key Market Drivers

Rising Prevalence of Hypertension

The rising prevalence of hypertension is a key factor influencing the growth of the global renal denervation market. Hypertension has become one of the most common chronic health conditions worldwide, driven by factors such as aging populations, sedentary lifestyles, poor dietary habits, obesity, and increased stress levels. For instance, according to WHO 2023, about 1.28 billion adults aged 30-79 suffer from hypertension globally, with two-thirds living in low- and middle-income countries. Nearly 46% are unaware of their condition, only 42% receive treatment, and just 21% have it under control. Reducing hypertension prevalence by 33% by 2030 remains a global health target. As the number of individuals diagnosed with high blood pressure continues to climb, so does the demand for more effective and sustainable treatment options. A significant proportion of patients experience resistant hypertension, where blood pressure remains high despite the use of three or more antihypertensive medications. This segment presents a major challenge in clinical practice and highlights the need for alternative solutions beyond drug therapy. Renal denervation has emerged as a promising intervention in such cases, offering a minimally invasive, device-based treatment that directly targets the overactive renal sympathetic nerves. For instance, according to the CDC, in 2022, high blood pressure was a primary or contributing factor in 685,875 deaths in the U.S. Around one in five COVID-19-related deaths occurred in individuals with a history of hypertensive disease, highlighting its significant role in overall mortality. The growing population of patients with uncontrolled or drug-intolerant hypertension makes renal denervation an attractive option for healthcare providers seeking to improve long-term outcomes. As awareness grows about the limitations of current pharmacological approaches, interest in non-pharmacologic interventions is rising. This trend is positioning renal denervation as an increasingly important tool in the global effort to manage hypertension more effectively and reduce its associated health risks.

Key Market Challenges

Lack of long-term clinical data

The lack of long-term clinical data remains one of the most significant challenges impacting the growth and acceptance of the global renal denervation market. While recent clinical trials have shown encouraging short-term results in reducing blood pressure among patients with resistant hypertension, healthcare providers and regulatory bodies still seek more comprehensive, long-term evidence to support widespread clinical adoption. Decision-makers in healthcare systems are cautious about incorporating device-based interventions without robust data that demonstrate sustained efficacy and safety over extended periods. Short-term reductions in blood pressure are promising, but the true value of renal denervation lies in its ability to maintain control over time and reduce the risk of major cardiovascular events. Without long-term follow-up data, it is difficult to evaluate whether the initial benefits translate into lasting improvements in patient outcomes, such as reduced incidence of stroke, heart attack, or kidney failure. The absence of extended trial data also creates uncertainty around patient selection, optimal procedural techniques, and the durability of nerve ablation. This uncertainty can hinder physician confidence, delay reimbursement decisions, and discourage investment in technology. Payers are particularly reluctant to fund procedures that lack evidence of cost-effectiveness over time, especially when compared to well-established pharmaceutical therapies. For renal denervation to gain broader acceptance as a routine clinical option, it must demonstrate long-term superiority or complementarity to drug therapy in managing resistant hypertension. Until large-scale, long-duration studies are completed and peer-reviewed, many stakeholders will remain hesitant. Ongoing research and continued post-market surveillance will play a critical role in addressing these concerns, but the current lack of longitudinal evidence remains a barrier to faster adoption. This gap in data not only affects market growth but also influences clinical guidelines and patient access to this potentially transformative therapy.

Key Market Trends

Technology evolution favoring ultrasound and micro-infusion

Technological evolution is playing a central role in the transformation of the global renal denervation market, with a growing shift toward ultrasound and micro-infusion-based systems. While radiofrequency ablation has historically been the standard approach, ultrasound technology is gaining momentum due to its ability to deliver circumferential energy around the arterial wall without requiring direct contact. This feature allows for more uniform nerve ablation and reduces the risk of procedural complications, making it an increasingly attractive option for physicians. The use of ultrasound catheters enables consistent and efficient denervation with shorter procedure times and improved safety profiles. These benefits are particularly important in clinical settings focused on precision and outcomes. Micro-infusion techniques, which involve delivering chemical agents directly into the perivascular space, are also emerging as a promising alternative. This method targets nerve endings with high specificity, allowing for controlled and localized ablation while minimizing damage to surrounding tissues. As companies invest in refining these systems, micro-infusion offers potential advantages for patients who may not be ideal candidates for thermal ablation. The advancement of these technologies is reshaping the competitive landscape, encouraging the development of next-generation devices that combine imaging guidance, real-time feedback, and customizable ablation protocols. With ongoing clinical trials and regulatory interest, ultrasound and micro-infusion platforms are driving innovation and expanding the range of renal denervation options available to physicians. These technologies align with the broader trend in medicine toward less invasive, more targeted interventions that prioritize both efficacy and patient safety. As adoption increases, they are expected to play a key role in elevating the clinical standards for treating resistant hypertension. The transition toward these newer methods reflects a market focused on improving procedural consistency, expanding treatment access, and enhancing long-term outcomes through continuous technological progress.

Key Market Players

• Medtronic Plc.
• Boston Scientific Corporation
• Abbott Laboratories, Inc.
• Terumo Corporation
• Johnson & Johnson
• Cordis Corporation
• ReCor Medical, Inc. (Otsuka Holdings)
• Cardiosonic Ltd.
• Mercator MedSystems, Inc.
• Renal Dynamics Limited

Report Scope:

In this report, the Global Renal Denervation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Renal Denervation Market, By Technology:

• Ultrasound Ablation
• Radiofrequency Ablation
• Pharmacologic Ablation
• Microinfusion

Renal Denervation Market, By Product:

• Catheters
• Single Electrode Catheter
• Multi Electrode Catheter
• RF Generator
• Others

Renal Denervation Market, By Therapeutic Area:

• Hypertension
• Heart Failure
• Diabetes
• Renal Failure
• Others

Renal Denervation Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Renal Denervation Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Renal Denervation Market.

Available Customizations:

Global Renal Denervation Market report with the given Market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional Market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Renal Denervation Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Ultrasound Ablation, Radiofrequency Ablation, Pharmacologic Ablation, Microinfusion)
  • 5.2.2. By Product (Catheters, Single Electrode Catheter, Multi Electrode Catheter, RF Generator, Others)
  • 5.2.3. By Therapeutic Area (Hypertension, Heart Failure, Diabetes, Renal Failure, Others)
  • 5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map
  • 5.3.1. By Technology
  • 5.3.2. By Product
  • 5.3.3. By Therapeutic Area
  • 5.3.4. By End User
  • 5.3.5. By Region

6. North America Renal Denervation Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Product
  • 6.2.3. By Therapeutic Area
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Renal Denervation Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Therapeutic Area
      • 6.3.1.2.4. By End User
  • 6.3.2. Mexico Renal Denervation Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Therapeutic Area
      • 6.3.2.2.4. By End User
  • 6.3.3. Canada Renal Denervation Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Therapeutic Area
      • 6.3.3.2.4. By End User

7. Europe Renal Denervation Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Product
  • 7.2.3. By Therapeutic Area
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Renal Denervation Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Therapeutic Area
      • 7.3.1.2.4. By End User
  • 7.3.2. Germany Renal Denervation Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Therapeutic Area
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Renal Denervation Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Therapeutic Area
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Renal Denervation Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Therapeutic Area
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Renal Denervation Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Therapeutic Area
      • 7.3.5.2.4. By End User

8. Asia-Pacific Renal Denervation Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Product
  • 8.2.3. By Therapeutic Area
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Renal Denervation Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Therapeutic Area
      • 8.3.1.2.4. By End User
  • 8.3.2. India Renal Denervation Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Therapeutic Area
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Renal Denervation Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Therapeutic Area
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Renal Denervation Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By Therapeutic Area
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Renal Denervation Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By Therapeutic Area
      • 8.3.5.2.4. By End User

9. South America Renal Denervation Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Product
  • 9.2.3. By Therapeutic Area
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Renal Denervation Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Therapeutic Area
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Renal Denervation Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Therapeutic Area
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Renal Denervation Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Therapeutic Area
      • 9.3.3.2.4. By End User

10. Middle East and Africa Renal Denervation Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Product
  • 10.2.3. By Therapeutic Area
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Renal Denervation Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Therapeutic Area
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Renal Denervation Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Therapeutic Area
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Renal Denervation Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Therapeutic Area
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Competitive Landscape

• 13.1. Medtronic Plc.
  • 13.1.1. Business Overview
  • 13.1.2. Company Snapshot
  • 13.1.3. Products & Services
  • 13.1.4. Financials (As reported)
  • 13.1.5. Recent Developments
  • 13.1.6. SWOT Analysis
• 13.2. Boston Scientific Corporation
• 13.3. Abbott Laboratories, Inc.
• 13.4. Terumo Corporation
• 13.5. Johnson & Johnson
• 13.6. Cordis Corporation
• 13.7. ReCor Medical, Inc. (Otsuka Holdings)
• 13.8. Cardiosonic Ltd
• 13.9. Mercator MedSystems, Inc
• 13.10. Renal Dynamics Limited

14. Strategic Recommendations

15. About Us & Disclaimer